arrow
M

Marc S. Raab

Heidelberg University Hospital
H指数:56
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

作者更正: 基于Teclistamab的诱导治疗符合移植条件的新诊断多发性骨髓瘤: 2期试验

2026-07-060
OAAI
Clinical decision support in hematological malignancies using a case-grounded AI agent

基于案例支持的AI代理在血液恶性肿瘤中的临床决策支持

2026-06-300
OAAI
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

基于Teclistamab的诱导治疗可移植的新诊断多发性骨髓瘤: 一项2期试验

2026-06-250
OAAI
Enhanced dynamic risk stratification of smoldering multiple myeloma

增强的冒烟性多发性骨髓瘤动态风险分层

2026-03-011
OA
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma

结构化全身MRI突显了复发/难治性多发性骨髓瘤临床相关疾病模式的变化。

Leukemia
IF13.4
2025-12-220
OAAI
Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose Melphalan

Talquetamab相关味觉障碍在多发性骨髓瘤中的比较:与BCMA靶向双特异性抗体及大剂量美法仑的比较

2025-12-080
OAAI
Characterization, outcome and identification of prognostic factors for patients with systemic immunoglobulin light-chain amyloidosis requiring dialysis prior to initial anti-clonal therapy

系统性免疫球蛋白轻链淀粉样变性患者在初始抗克隆治疗前行透析治疗时的特征、结局及预后因素识别

2025-12-010
OA
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

BCMA-和GPRC5D靶向免疫疗法在多发性骨髓瘤中的序贯治疗:欧洲骨髓瘤网络实用指南

2025-11-250
OAAI
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial

IgG或IgA多发性骨髓瘤患者中Hevylite检测的预后影响:GMMG-MM5试验结果

2025-11-010
OAAI
Prospective systematic classification of causes of death in the course of multiple myeloma

多发性骨髓瘤病程中死亡原因的前瞻性系统分类

2025-10-200
OA
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma

欧洲骨髓瘤网络工作组关于下一代测序在 newly diagnosed multiple myeloma 预后分层中应用的共识声明

2025-10-130
OAAI
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma

基于基线MRI的自动放射组学模型,用于预测多发性骨髓瘤的治疗反应和微小残留病灶

2025-10-100
OA
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial

验证用于量化多发性骨髓瘤患者四肢骨骼骨髓的新型低剂量CT方法:来自Phase 3 GMMG-HD7试验[18F]FDG PET/CT亚研究的初步结果

2025-10-010
OA
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma

内源性T细胞景观被CAR-T细胞疗法重塑,并预测多发性骨髓瘤的治疗反应

Leukemia
IF13.4
2025-09-190
OAAI
Temporal genomic dynamics shape clinical trajectory in multiple myeloma

时间基因组动力学塑造多发性骨髓瘤的临床轨迹

2025-08-200
OA
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Eha-emn循证指南用于多发性骨髓瘤患者的诊断、治疗和随访

2025-07-070
PREAI
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network

优化多发性骨髓瘤患者的T细胞免疫疗法:欧洲骨髓瘤网络的经验与考量

2025-06-250
PRE